SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's expansion into a pioneer in digital asset treasury management. Alongside the rebrand, the Company's ticker symbol on the NASDAQ Stock Market will transition from MEIP to LITS, effective at market open on September 11, 2025. The rebranding to Lite Strategy, Inc. underscores the Company's commitment to building.

[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. According to foreign media reports such as Investing, with the continuous inflow of US spot ETF funds, the acceleration of technology implementation by the Ethereum Layer 2 Industry Alliance, and the launch of the network upgrade of Dogecoin (DOGE), Bitcoin's "safe-haven attribute" as a market value anchor has once again attracted capital favor, and its network computing power and BTC mining income have increased significantly. Another major positive news this week also boosted BTC confidence: MEI Pharmaceuticals (NASDAQ: MEIP) announced that Litecoin (LTC) will be included in the corporate treasury portfolio and completed the allocation of digital assets worth $100 million, which has aroused the capital market's deep attention to the reserve allocation model of encrypted assets. This behavior not only verifies the trust of mainstream institutions in encrypted assets, but also indirectly drives the prices of major currencies including Bitcoin to rise simultaneously. Hashj made timely adjustments to the market and provided new members with a maximum registration reward of $118 for BTC mining experience.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy.

MEI Pharma, Inc. MEIP stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for expected aggregate gross proceeds of approximately $100 million, before deducting placement agent fees and other estimated offering expenses. In connectio.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockh.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its st.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process. In order to best preserve the Company.

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.